Shahram Jacobs

Internal Medicine

4955 Van Nuys Boulevard
Suite 200
Sherman Oaks, CA 91403

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1 publications

Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study.

Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study.

Journal: Journal of the American Academy of Dermatology

Published: June 27, 2025

Showing 1-1 of 1

Last Updated: 09/26/2026